Free tool
FAERS Monitor: Alyftrek
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218730 or its brand name (Alyftrek, Deutivacaftor, Tezacaftor, Vanzacaftor Calcium). Reports on generic versions are filed under their own applications.
Reports
789
Serious
375
48% of reports
Hospitalization
222
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hospitalisation68
- headache53
- anxiety48
- rash47
- fatigue45
- dyspnoea39
- infective pulmonary exacerbation of cystic fibrosis34
- diarrhoea33
- liver function test increased33
- nausea33
- haemoptysis24
- alanine aminotransferase increased23
- gastrointestinal disorder23
- mental disorder23
- abdominal pain upper22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 344 |
| 2026 | 443 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,370 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 34 | 167.6 | 120.5 | 5,432 |
| liver function test increasedSignal | 33 | 41.0 | 29.4 | 1,249 |
| haemoptysisSignal | 24 | 23.0 | 15.5 | 483 |
| mental disorderSignal | 23 | 14.1 | 9.4 | 267 |
| hospitalisationSignal | 68 | 11.8 | 9.4 | 666 |
| alanine aminotransferase increasedSignal | 23 | 10.0 | 6.7 | 178 |
| gastrointestinal disorderSignal | 23 | 6.8 | 4.6 | 109 |
| anxietySignal | 48 | 4.5 | 3.4 | 129 |
| rashSignal | 47 | 2.9 | 2.2 | 57 |
| abdominal pain upperSignal | 22 | 2.8 | 1.9 | 25 |
| headacheSignal | 53 | 2.3 | 1.7 | 37 |
| dyspnoea | 39 | 1.8 | 1.4 | 14 |
| fatigue | 45 | 1.5 | 1.2 | 8 |
| diarrhoea | 33 | 1.4 | 1.0 | 3 |
| nausea | 33 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.